ByteDance has spun off its AI drug development unit ANEW LABS, which completed a $290 million funding round.
The financing supports ANEW LABS as an independent AI-focused drug discovery company following its separation from ByteDance.
ByteDance Spins Off AI Drug Discovery Unit ANEW LABS, Raises $290M
Disclaimer: The content provided on Phemex News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of the information sourced from third-party articles. The content on this page does not constitute financial or investment advice. We strongly encourage you to conduct you own research and consult with a qualified financial advisor before making any investment decisions.